Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

News Releases

Date Title and Summary
Toggle Summary electroCore Receives FDA Clearance for gammaCore™ (nVNS) for Adjunctive Use for the Preventive Treatment of Cluster Headache in Adults
BASKING RIDGE, N.J. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration ( FDA ) for an expanded label for gammaCore™ [non-invasive vagus
Toggle Summary electroCore Expands Manufacturing Capabilities for gammaCore™
BASKING RIDGE, N.J. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc.  (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced expansion into a new design and development facility to support increasing patient demand of its gammaCore™ non-invasive vagus
Toggle Summary electroCore, Inc. to Present at the Evercore ISI HealthCONx Conference
BASKING RIDGE, N.J. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the company will be participating in the upcoming Evercore ISI HealthCONx Conference in Boston, MA.
Toggle Summary electroCore, Inc. Announces Third Quarter Financial Results
BASKING RIDGE, N.J. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today reported financial results for the three months and nine months ended September 30, 2018 .
Toggle Summary NICE publishes advice on gammaCore for the treatment of cluster headache in the UK
Report contributors agreed gammaCore was highly innovative, may be more effective than standard of care alone, and has the potential to save money through the NHS by reducing the cost of treating cluster headache BASKING RIDGE, N.J. , Nov. 09, 2018 (GLOBE NEWSWIRE) --  electroCore, Inc.,
Toggle Summary electroCore, Inc. to Report Third Quarter Financial Results on November 13, 2018
BASKING RIDGE, N.J. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it will release financial results for the third quarter ended September 30, 2018 after the close of trading on Tuesday,
Toggle Summary electroCore, Inc. Announces Appointment of Ardelle Ferris as Vice President of Managed Care
BASKING RIDGE, N.J. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc.  (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Ardelle Ferris to a new position within the company, Vice President of Managed Care.
Toggle Summary NICE publishes advice on gammaCore for the treatment of cluster headache in the UK
– Report contributors agreed gammaCore was highly innovative, may be more effective than standard of care alone, and has the potential to save money through the NHS by reducing the cost of treating cluster headache – Basking Ridge, NJ, October 22, 2018 – electroCore, Inc.
Toggle Summary electroCore, Inc. to Present at the Cantor Global Healthcare Conference
BASKING RIDGE, N.J. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced the company will be participating in the upcoming Cantor Global Healthcare Conference in New York, NY .
Toggle Summary electroCore to Present Additional Research for Non-invasive Vagus Nerve Stimulation in Headache Disorders at the 17th Biennial Migraine Trust International Symposium
BASKING RIDGE, N.J. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that seven abstracts and an oral presentation featuring non-invasive vagus nerve stimulation (nVNS) across two primary headache disorders